Healthcare provider profile · identity verified

Lawrence William Roth, MD

Internal Medicine · ENGLEWOOD, CO · NPI 1225133390

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	830	246
Simvastatin	Simvastatin	539	154
Lisinopril	Lisinopril	509	157
Levothyroxine Sodium	Levothyroxine Sodium	485	144
Amlodipine Besylate	Amlodipine Besylate	340	106
Metformin Hcl	Metformin Hcl	339	107
Omeprazole	Omeprazole	293	114
Tamsulosin Hcl	Tamsulosin Hcl	285	92
Losartan Potassium	Losartan Potassium	278	91
Rosuvastatin Calcium	Rosuvastatin Calcium	278	91
Sertraline Hcl	Sertraline Hcl	230	73
Pradaxa	Dabigatran Etexilate Mesylate	210	71
Alendronate Sodium	Alendronate Sodium	205	72
Gabapentin	Gabapentin	204	83
Metoprolol Tartrate	Metoprolol Tartrate	191	58
Arexvy	Rsvpref3 Antigen/As01e/Pf	179	179
Trazodone Hcl	Trazodone Hcl	154	51
Albuterol Sulfate Hfa	Albuterol Sulfate	140	76
Atenolol	Atenolol	138	42
Furosemide	Furosemide	132	50
Mirtazapine	Mirtazapine	129	45
Allopurinol	Allopurinol	126	37
Duloxetine Hcl	Duloxetine Hcl	126	43
Glipizide	Glipizide	123	40
Meloxicam	Meloxicam	119	71
Doxazosin Mesylate	Doxazosin Mesylate	111	34
Metoprolol Succinate	Metoprolol Succinate	110	38
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	106	35
Potassium Chloride	Potassium Chloride	96	31
Finasteride	Finasteride	95	31
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	94	94
Jardiance	Empagliflozin	90	25
Pantoprazole Sodium	Pantoprazole Sodium	90	33
Tramadol Hcl	Tramadol Hcl	88	20
Metformin Hcl Er	Metformin Hcl	87	32
Citalopram Hbr	Citalopram Hydrobromide	81	25
Bupropion Xl	Bupropion Hcl	78	26
Warfarin Sodium	Warfarin Sodium	78	24
Wixela Inhub	Fluticasone Propion/Salmeterol	78	31
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	76	23
Hydrochlorothiazide	Hydrochlorothiazide	72	25
Venlafaxine Hcl Er	Venlafaxine Hcl	72	25
Ezetimibe	Ezetimibe	69	22
Clopidogrel	Clopidogrel Bisulfate	68	24
Triamcinolone Acetonide	Triamcinolone Acetonide	65	39
Morphine Sulfate Er	Morphine Sulfate	63	suppressed
Alvesco	Ciclesonide	60	29
Humulin N	Insulin Nph Human Isophane	60	25
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	59	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	58	18
Fluticasone Propionate	Fluticasone Propionate	57	22
Solifenacin Succinate	Solifenacin Succinate	57	21
Spiriva Respimat	Tiotropium Bromide	55	21
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	52	22
Oxycodone Hcl	Oxycodone Hcl	52	16
Carvedilol	Carvedilol	50	16
Escitalopram Oxalate	Escitalopram Oxalate	48	16
Prednisone	Prednisone	46	35
Latanoprost	Latanoprost	42	suppressed
Estradiol	Estradiol	40	23
Lovastatin	Lovastatin	39	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	39	37
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	37	suppressed
Eliquis	Apixaban	36	12
Famotidine	Famotidine	36	14
Pregabalin	Pregabalin	34	suppressed
Donepezil Hcl	Donepezil Hcl	32	11
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	29	16
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	29	suppressed
Spironolactone	Spironolactone	29	suppressed
Pravastatin Sodium	Pravastatin Sodium	28	suppressed
Ozempic	Semaglutide	27	suppressed
Buspirone Hcl	Buspirone Hcl	26	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	24	23
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	23	11
Acyclovir	Acyclovir	22	11
Pioglitazone Hcl	Pioglitazone Hcl	22	suppressed
Azelastine Hcl	Azelastine Hcl	21	suppressed
Methocarbamol	Methocarbamol	21	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Humulin R	Insulin Regular, Human	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	19	11
Glimepiride	Glimepiride	18	suppressed
Naloxone Hcl	Naloxone Hcl	18	18
Cefuroxime	Cefuroxime Axetil	17	16
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	17	17
Digoxin	Digoxin	17	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	17	suppressed
Baclofen	Baclofen	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	16	suppressed
Nitroglycerin	Nitroglycerin	16	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Celecoxib	Celecoxib	14	suppressed
Lorazepam	Lorazepam	14	11
Memantine Hcl	Memantine Hcl	14	suppressed
Topiramate	Topiramate	14	suppressed
Xifaxan	Rifaximin	14	suppressed
Buprenorphine	Buprenorphine	13	suppressed
Colchicine	Colchicine	13	suppressed
Methadone Hcl	Methadone Hcl	13	suppressed
Naltrexone Hcl	Naltrexone Hcl	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	13	suppressed
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Midodrine Hcl	Midodrine Hcl	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Cartia Xt	Diltiazem Hcl	11	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Morphine Sulfate	Morphine Sulfate	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error